Market reaction
H.B. Fuller stock dropped 6.4% in pre-open trading to $60.45 following the company's announcement that it will acquire Advanced Medical Solutions. The confirmation of the transaction came on the heels of the firm's fiscal second-quarter results, and investors responded sharply in early trading.
Background on the takeover and activist concerns
Ancora Holdings, an activist investor, publicly urged H.B. Fuller in late May 2026 to abandon its pursuit of Advanced Medical Solutions and to initiate a full strategic review instead. Ancora highlighted specific worries that the purchase would raise leverage, put pressure on valuation, and present integration challenges for management in a cross-border deal.
Those warnings took on new significance once H.B. Fuller confirmed the agreed price for Advanced Medical Solutions at a3715 million, which equates to approximately $942 million when including assumed debt. Market participants noted that the acquisition was likely to push the company's leverage above 4.0x Net Debt/Proforma Adjusted EBITDA - a threshold flagged as potentially problematic for the firm's capital structure and valuation.
Earnings and guidance details
H.B. Fuller released fiscal second-quarter results after the market close on June 24. The company reported revenue that exceeded expectations, but earnings per share were exactly in line with analyst estimates. While the top-line beat drew attention, the in-line EPS print left investors focused on the details of the quarter and on the updated full-year outlook.
The midpoint of H.B. Fullers adjusted EPS guidance was announced at $4.75, narrowly below the analyst consensus of $4.77. That slight shortfall at the guidance midpoint was interpreted by the market as a sign that management was not setting an especially ambitious target following a recent run-up in the stock.
How the pieces fit together
Taken together, the confirming of a substantial, debt-including acquisition; an earnings report that neither raised nor lowered expectations; and a guidance midpoint that missed consensus by a small margin combined to generate heightened selling pressure in pre-market trading. Observers described the situation as a confluence of factors that amplified investor concern about near-term capital allocation and balance sheet flexibility.
Market commentary indicated that the decline was driven primarily by forward guidance. The EPS midpoint sitting under the consensus estimate suggested that investors had been anticipating a firmer outlook. Layering the Advanced Medical Solutions deal on top of that projection - a deal that increases leverage materially - deepened investor unease.
Wider market context
The broader U.S. equity market offered little offset to the weakness in H.B. Fuller shares. The S&P 500 edged down 0.1% while the Nasdaq slipped 0.4%, reflecting a cautious tone across major indexes. H.B. Fuller had gained more than 9% over the prior month, meaning recent gains may have heightened sensitivity to news on guidance or capital allocation and contributed to the outsized pre-market reaction.
Conclusion
The combination of an acquisition that increases leverage to an elevated level, a guidance midpoint just below analyst expectations, and an earnings result that matched estimates appears to have driven the pre-market selloff. Investors are now left to weigh the implications of a large, debt-funded cross-border purchase against a modestly conservative full-year EPS midpoint.